Publications: Stephen Ezell

Global Trade and Innovation Policy Alliance (GTIPA) members from 17 countries analyzed how their economies are reacting to U.S. tariffs. Many countries are seeking to support their local producers and establish trade arrangements that are less reliant on the United States.

Small manufacturers power U.S. industry, but many are struggling to compete. Cutting the MEP program would weaken the backbone of America's manufacturing economy.

Universities play a pivotal role in America’s technology economy, serving as a crucial source of research, inventions, patents, start-up technology companies, and regional economic and employment growth. The Bayh-Dole Act has played an instrumental role in spurring academic technology transfer activities that serve as vital drivers of American innovation.

The CHIPS Act tax credit powered America's chip resurgence and letting it expire would stall the momentum.

Imposing blanket tariffs on U.S. semiconductor imports would imperil U.S. leadership across a broad range of digital and nondigital industries while significantly decreasing U.S. economic growth, raising prices, and jeopardizing broader U.S. manufacturing competitiveness.

The Trump administration’s call for “most favored nation” drug price controls will lead to less biopharmaceutical innovation and reduced U.S. drug industry competitiveness. However, the president’s willingness to use tariff negotiations to press other nations to pay their fair share for patented drugs is salutary.

The Trump administration’s “MFN” drug-price proposal would pose a far greater threat to U.S. biopharma innovation than the Inflation Reduction Act, because unlike the IRA’s selective list, MFN could apply across virtually every medicine, multiplying the deleterious impact.

As part of its deregulation efforts, the administration should clarify Bayh-Dole march-in rights; rescind NIH Access Planning Policy; rescind FRA two-person train crew requirements; clarify requirements for manually operated driving controls; protect America’s innovative clean-energy technologies; and streamline regulatory permitting for semiconductors.

Instead of blanket tariffs, America should focus first on persuading other nations to pay their fair share, and then on supporting public-private investments in novel technologies that will make U.S. pharmaceutical producers more innovative and cost-competitive.

The administration should focus foremost on addressing China’s mercantilist policies and resist the urge to impose blanket tariffs on U.S. imports of semiconductors, semiconductor inputs, or products with embedded semiconductors.